Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2

Cancer Immunology, Immunotherapy

Volumn 54, Issue 8, 2005, Pages 792-798

  Jacobs, John J L ^a   Hordijk, Gerrit J ^b   Jürgenliemk Schulz, Ina M ^b   Terhaard, Chris H J ^b   Koten, Jan W ^a   Battermann, Jan J ^b   Den Otter, Willem ^a  

^a Faculty of Veterinary Medicine   (Netherlands)

^b Utrecht School of Governance   (Netherlands)

Author keywords

Human cancer; Interleukin 2; Local IL 2; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLINDNESS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INJECTION SITE REACTION; INTERMETHOD COMPARISON; LONG TERM CARE; LOW DRUG DOSE; MALE; NASOPHARYNX CARCINOMA; OPTIC NERVE DISEASE; PAIN; PRIORITY JOURNAL; SCAR FORMATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ULCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 22144471231     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0641-6     Document Type: Article

References (29)

1. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W (2002) The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51:492
2. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (1992) American Joint Committee on Cancer: manual for staging of cancer, p 33
3. Chan ATC, Leo PML, Johnson PJ (2002) Nasopharyngeal carcinoma. Ann Oncol 13:1007
4. Chi KH, Meyers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT (2001) Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60:110
5. Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Jemma C, Giovarelli M, Vai S, Forni G (1991) Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 13:125
6. De Mik HJ, Koten JW, Maas RA, Dullens HF, Den Otter W (1991) Tumour regression by IL-2 mediated stagnation of blood flow. In Vivo 5:679
7. Den Otter W, Cadee J, Gavhumende R, De Groot CJ, Hennink WE, Stewart R (1999) Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour. Cancer Immunol Immunother 48:419
8. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van Der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159:1183
9. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Stewart R, Faber JA, Ruitenberg EJ, Rutten VPMG (1995) Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41:10
10. Den Otter W, Maas RA, Koten JW, Dullens HFJ, Bernsen M, Klein WR, Rutten VPMG, Steerenberg PA, Balemans L, Ruitenberg EJ et al (1991) Effective immunotherapy with local low doses of interleukin-2. In Vivo 5:561
11. Edwards M, Miller F, Sims D, Abney D, Schuschke D, Corey T (1992) Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage. Cancer Res 52:3425
12. Edwards M, Schuschke D, Abney D, Miller F (1991) Interleukin-2 acutely induces protein leakage from the microcirculation. J Surg Res 50:609
13. Farias TP, Dias FL, Lima RA, Kligerman J, de Sa GM, Barbosa MM, Goncalves FBJ (2003) Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 129:794
14. Harada Y, Yahara I (1993) Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int Rev Exp Pathol 34:37
15. Jacobs JJL, Sparendam D, Den Otter W (2005) Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother (in press)
16. Jurgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ (1997) Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Radiat Oncol Investig 5:54
17. Koukourakis MI, Whitehouse RM, Giatromanolaki A, Saunders M, Kaklamanis L (1996) Predicting distant failure in nasopharyngeal cancer. Laryngoscope 106:765
18. Krastev Z, Koltchakov V, Popov D, Alexiev A, Koten J-W, Den Otter W (2003) A case of hepatocellular carcinoma (HCC): treatment with local application of alcohol and interleukin 2 (IL-2). Cancer Immunol Immunother 50:1647
19. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W (2001) A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50:226
20. Kusnierczyk H, Pajtasz-Piasecka E, Koten J-W, Bijleveld C, Krawczyk KP, Den Otter W (2004) Multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 53:445
21. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21:631
22. Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49:7037
23. Marks JE, Phillips JL, Menck HR (1998) The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 83:582
24. Mould RF, Tai THP (2002) Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Br J Radiol 75:307
25. Reddy SP, Raslan WF, Gooneratne S, Kathuria S, Marks JE (1995) Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 16:103
26. Rosenblatt E, Brook OR, Erlich N, Miller B, Joachims HZ, Kuten A (2003) Late visual and auditory toxicity of radiotherapy for nasopharyngeal carcinoma. Tumori 89:68
27. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:1735
28. Shanmugaratnam K, Sobin L (eds) (1978) Histological typing of upper respiratory tract tumors, p 32
29. Yu MC, Yuan J-M (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12:421